New Insight with Dr. Veeral Sheth

Diabetes Dialogue

Don’t Miss a Beat

Crisis Point

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

A new gut microbiome analysis has found significant differences in diversity between people with and without 

“Despite significant information in the literature on FM pathophysiology and potential diagnostic mechanisms, it remains insufficient, as there is no definitive diagnostic procedure based on biological biomarkers,” lead investigator Lauma Ievena, PhD candidate,
The Institute of Microbiology and Virology of the Riga Stradiņš University Science Hub, Latvia, and colleagues wrote.

 “Thus, our study aims to identify the prevalence of HHV-6 A and B infection and changes in pro-inflammatory cytokines and microbiome, as well as measure the potential link between these parameters. Our goal is to gain information about measurable indicators with a biomarker potential that could help diagnose and assess FM by analyzing viral infections, cytokine profiles, gut microbiome, and their interactions.

Ievena and colleagues analyzed data from 17 participants diagnosed with FM and 24 apparently healthy participants. They used real-time polymerase chain reaction (qPCR), to detect the presence of human herpesvirus (HHV)-6A and B genomic sequences in DNA isolated from peripheral blood mononuclear cells (PBMCs) and buccal swabs. They measured HHV-6-specific IgG and IgM class antibodies and proinflammatory cytokine levels, using enzyme-linked immunosorbent assay (ELISA) and bead-based multiplex assays. They also analyzed the gut microbiome using next-generation sequencing.

The investigators found that HHV-6B was present in the PBMCS of 4 participants and the buccal swabs of 3 (23.5%) with FM compared with presence in the PBMCs of 4 control group participants (16.6%), although this difference was not statistically significant (

Comparing cytokine levels between HHV-6B DNA-positive and negative patients with FM revealed significantly elevated levels of TNF-α (

 = .03) in those that were positive. Notably, participants with FM and a body mass index (BMI) of 30 or higher had elevated of IL-1β, IL-2, TNF-α, and IL-17A/CTLA levels compared to those with the same BMI range in the control group, although these differences were also not statistically significant.

Ievena and colleagues also found that the gut microbiome in participants with FM was less diverse than in the control group, as shown on a-diversity metrics with both Shannon’s (

 = 0.03) indices being significantly higher in control group participants (4.11 ± 0.4 and 30.74 ± 13.9, respectively) than in participants with FM (3.78 ± 0.5 and 20.98 ± 13.7, respectively. Specifically, they found that FM gut microbiomes had depleted 

 bacterium NSJ 40 species; and enriched 

 sp. NSJ 60, and GGB79630 SGB13983 assembled genome of 

 phylum species than those in the control group (all 

“This pilot study indicates a tendency where HHV-6B genome sequences are more frequently found in FM patients accompanied by higher plasma levels of TNF-α, compared to healthy individuals,” Ievena and colleagues concluded.

 “Additionally, significant differences were observed in the Shannon α-diversity and β-diversity of the gut microbiome between FM patients and matched healthy controls, indicating a shift in species abundance in the FM group.”

Ievina L, Fomins N, Gudra D, Kenina V, Vilmane A, Gravelsina S, Rasa-Dzelzkaleja S, Murovska M, Fridmanis D, Nora-Krukle Z. Human Herpesvirus-6B Infection and Alterations of Gut Microbiome in Patients with Fibromyalgia: A Pilot Study. 

. 2024; 14(10):1291. doi: 10.3390/biom14101291

Wang Y, Wei J, Zhang W, et al. Gut dysbiosis in rheumatic diseases: A systematic review and meta-analysis of 92 observational studies. 

, 104055. doi: 10.1016/j.ebiom.2022.104055

Articles

A recent study explored the gut microbiome and viral infections in fibromyalgia (FM) patients, revealing notable differences in microbiome diversity compared to healthy individuals. The research aimed to identify potential biomarkers for FM diagnosis by examining human herpesvirus-6 (HHV-6) infections, cytokine profiles, and microbiome interactions. The study found a higher prevalence of HHV-6B in FM patients, along with elevated TNF-α levels. Additionally, FM patients exhibited reduced gut microbiome diversity and distinct microbial species compared to controls, suggesting potential diagnostic and therapeutic implications.

The study also identified a tendency for more prevalent human herpesvirus 6B in people with FM than in those without.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Fibromyalgia

On the HCPLive fibromyalgia page, resources on the topics of medical news and expert insight into fibrositis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on fibromyalgia, and more.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Study Identifies Gut Microbiome Makeup, Diversity Differences in People With Fibromyalgia

Chelsie Derman is an assistant editor for 

who covers psychiatry, sleep medicine, and geriatrics. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Half of all patients with sepsis admitted to an emergency department died within 2 years, a recent study discovered.

“We found that certain factors increased the risk of death after sepsis, including, not surprisingly, advanced age,” said lead investigator Finn E. Nielsen, a senior scientist in the Department of Clinical Epidemiology at Aarhus University Hospital, Denmark, in a statement.

A global report from the World Health Organization in 2020 recognized the knowledge gaps on epidemiology and burden of sepsis.

 Estimates of sepsis incidence and mortality differ considerably depending on study designs, data sources, and sepsis definitions.

WHO recognizes the need for improved long-term outcome data among sepsis patients. Previous sepsis epidemiological analyses are based on systematic reviews that mostly examine retrospective observational cohort or cross-sectional studies. WHO believes prospective studies using charts or electronic health records are needed to assess sepsis epidemiology.

In line with WHO’s recommendation, investigators conducted a prospective study of adult patients admitted to an emergency department with sepsis, aiming to determine long-term all-cause mortality and predictors for mortality in this patient population.

 The findings were presented at the European Emergency Medicine Congress in Copenhagen.

The primary outcome was all-cause mortality, specifically time to death, within the long-term follow-up period. Nielson and colleagues also tried to develop a model that could predict the risk of death over the longer term.

Patients were all admitted to the emergency department with suspected infectious diseases from October 1, 2017, to March 31, 2018. The mortality data of patients were obtained from The Regional Zealand Patient Registration System, which is linked to the Danish Civil Registration System that provides daily updated information on the vital status of all Danish citizens. From another database, investigators collected data on demographics, comorbidities, triage variables, laboratory tests, infectious sources, other diagnostic procedures, and clinical progressions during hospitalization.

“Our study relied on a sepsis database, which provided valuable information based on prospectively collected patient data,” Nielson said.

 “Unlike frequently used routine registry data, this approach minimised errors and allowed for more accurate and detailed insights into sepsis effects.”

The study included 2110 patients with suspected infections and 714 (33.8%) patients who developed sepsis, defined as a Sequential Organ Failure Assessment Score ≥ 2.

Among patients with sepsis, 58.4% were male and the median age was 75 years when sepsis developed.

After a median follow-up of 2 years, 50.6% of the patients died. Factors independently associated with the increased risk of mortality among those with sepsis included age (hazard ratio [HR], 1.04; 95% confidence interval [CI], 1.03 – 1.05), a history of cancer (HR, 2.21; 95% CI, 1.70 – 2.87), ischemic heart disease (HR, 1.39; 95% CI, 1.05 – 1.85), dementia (HR, 1.90; 95% CI, 1.41 – 2.57), and previous admission with sepsis (HR, 1.48; 95% CI, 1.19 – 1.84) within the last 6 months before hospital admission.

Since this study was conducted in a single center, the team wrote how a larger prospective study needs to be carried out.

“Although we identified several risk factors that clearly increased the risk of death and should provide a focus for clinicians and researchers during the discharge planning process, as well as for developing future prediction studies, we were unable to construct an overall model suitable for predicting mortality in clinical practice,” Nielson said.

 “There is a need for prospective studies of the effect of other factors that are not examined in our study, including various complications that may arise following hospitalisation and after discharge.”

Abdullah, O, Andersen, L, Sorensen, R, et al. Long-term Mortality Among Sepsis Patients: A Prospective Single-Center Study. Presented at European Emergency Medicine Congress in Copenhagen on October 15, 2024, in Copenhagen, Denmark.

Half of All Patients with Sepsis Die Within Two Years. EurekAlert! October 14, 2024. 

https://www.eurekalert.org/news-releases/1060870

Global report on the epidemiology and burden of sepsis: current evidence, identifying gaps and future directions. Geneva: 

; 2020. Licence: CC BY-NC-SA 3.0 IGO. Accessed October 16, 2024. 

A recent study revealed that half of sepsis patients admitted to an emergency department died within two years. The study, aligning with WHO's call for improved long-term sepsis data, identified factors like advanced age, cancer history, ischemic heart disease, dementia, and recent sepsis admissions as increasing mortality risk. Conducted at a single center, the study used a sepsis database for accurate data collection. Despite identifying risk factors, the study couldn't develop a comprehensive mortality prediction model, highlighting the need for larger prospective studies.

A new prospective study discovered predictors for mortality among patients with sepsis admitted to the emergency department, including age, history of cancer, and dementia.

Hospital Medicine

The HCPLive hospital medicine page is a comprehensive resource for clinical news and insights on the emergency medicine specialty. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for emergent care, and more.

50% of Patients with Sepsis Admitted to the Emergency Department Die Within 2 years

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

 using dose optimization for risankizumab will find it efficacious and safe, according to new findings, aligning with the positive results of dose optimization seen with other biologics.

These findings represent the conclusion of a recent letter to the editor highlighting research into optimizing dosing for risankizumab, an interleukin (IL)-23 inhibitor for the chronic inflammatory skin disease psoriasis. This research was authored in part by Jensen Yeung, from the division of dermatology at Women's College Hospital in Toronto, Canada.

“While optimized dosing strategies have been elucidated for other biologics, risankizumab's potential has not been fully explored,” Yeung and colleagues wrote. “This study aims to explore the effectiveness and safety of risankizumab dose optimization in adult patients with moderate-to-severe plaque psoriasis.”

A multicenter, international, retrospective study was conducted by the investigators, during which the team reviewed patient records from tertiary academic dermatology clinics found within both Canada and Portugal. They determined their primary outcome would be a 90%-or-greater improvement in participants’ Psoriasis Area and Severity Index (PASI90) scores and the achievement of a Physician Global Assessment (PGA) score of clear or almost clear (PGA 0/1).

The research team made up their study population of adults aged 18 years and older who had moderate-to-severe psoriasis. These subjects were treated with the standard on-label risankizumab regimen of 150 mg administered subcutaneously at the 0 and 4-week mark, followed every 12 weeks.

Adjustments to treatments, including shifts in the dosing intervals, were decided upon based on individual needs of the participants. The team monitored participant safety in their documentation of adverse events (AEs) and rates of treatment cessation.

Among the 511 subjects in the study treated with subcutaneous risankizumab, 16% were shown to require dose optimization. These subjects’ average age was found to be 51.4 years, with 63.4% of the group being male.

Before beginning risankizumab, these individuals had failed approximately 1.1 non-biologic systemic treatments and 0.91 biologics. Among the prior biologics were guselkumab, adalimumab, and ustekinumab, while the most commonly used non-biologic options were acitretin, methotrexate, and cyclosporine.

The research team reported that the average PASI score among subjects was 3.7 at the time of the subjects dose optimization. The team added that participants had been on the standard dose of risankizumab for an average of 212.2 days.

The investigators found that 72% of subjects switched to an 8-week dosing schedule, noting that this was chiefly due to their initial regimen response being inadequate. Only 4.8% were reported to have chosen to extend their predetermined dosing intervals for personal reasons, and these individuals had a PASI score of 0 prior to the optimization decision.

Following the trial participants’ dose optimization, the researchers noted that the average follow-up period had been 190.2 days, concluding that 90.2% of participants were successful in achieving either PASI90 or a PGA 0/1 score. The team also highlighted that 37.8% reached PASI100 and that 80.5% attained a PASI score of 2 or lower.

They added that 54.9% had a PASI score which was under 1. The subjects who opted for a longer dosing interval maintained their PASI response, while 89.7% of the subjects who optimized to a shorter interval were successful in achieving PASI90 or PGA 0/1.

The investigators highlighted the fact that only 3 participants reported at least a single AE, suggesting that AEs were rare. A single case of alopecia resulted in cessation of treatment, and there was 1 unrelated thrombosis event reported.

All AEs transpired in individuals who had a shortened dosing schedule. After the dose was optimized, it was found that 18.3% of subjects discontinued risankizumab. 73% of these discontinuations resulted from insufficient efficacy.

“Dose optimization of biologics is relatively well-studied in moderate-to-severe plaque psoriasis, with our previous reports affirming enhancement of patient outcomes without compromising safety,” they wrote. “Our current study aligns with these findings, marking, to our knowledge, the first to showcase the effectiveness and safety of dose optimized risankizumab for plaque psoriasis.”

The investigators did acknowledge, however, that their outcomes’ generalizability may be held back by their study’s heterogeneous population and its limited sample size, suggesting a need for rigorous and controlled studies.

Bagit, A., Maliyar, K., Mansour, M., Georgakopoulos, J.R., Rankin, B., Lytvyn, Y., Zaaroura, H., Park, Y.J., Wang, E., Mufti, A., Torres, T., Le, A.M., Vender, R., Prajapati, V.H. and Yeung, J. (2024), Effectiveness and safety of risankizumab dose optimization in adult patients with plaque psoriasis: An international multicentre retrospective cohort study. J Eur Acad Dermatol Venereol. https://doi.org/10.1111/jdv.20373.

Benzaquen M, Munshi M, Bossart S, Feldmeyer L, Emelianov V, Yawalkar N, et al. Long-term dose optimization of adalimumab via dose spacing in patients with psoriasis. Bioengineering (Basel). 2022; 9(8): 387.

Recent research indicates that dose optimization of risankizumab, an IL-23 inhibitor, is both effective and safe for patients with moderate-to-severe plaque psoriasis. Conducted across Canada and Portugal, the study involved 511 patients, with 16% requiring dose adjustments. Results showed that 90.2% achieved significant improvement in PASI90 or PGA scores post-optimization. Adverse events were rare, with only three cases reported. The study underscores the potential of risankizumab dose optimization, though its generalizability is limited by the study's heterogeneous population and sample size.

This analysis aligns with previous research into dose optimization of biologics for psoriasis, affirming enhancement of outcomes without compromising patient safety.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Risankizumab (Skyrizi) Dose Optimization Effective, Safe for Patients with Psoriasis

Dominic Sisti, PhD, is an associate professor in the Department of Medical Ethics & Health Policy and the director of the Scattergood Program for the Applied Ethics of Behavioral Health Care. Sisti is also the host of 

, our monthly multimedia series on medical ethics in modern healthcare. 

Medical Ethics Unpacked Introductory Episode

In the introductory episode of the new podcast "Medical Ethics Unpacked," hosts Dominic Sisti, PhD, and Steve Levine, MD, invite listeners on a deep dive into the challenging and often controversial issues facing the healthcare industry.

Sisti, associate professor in the Department of Medical Ethics & Health Policy and the director of the Scattergood Program for the Applied Ethics of Behavioral Health Care at the University of Pennsylvania, and Levine, a psychiatrist and the senior vice president of Patient Access at Compass Pathways, bring unique perspectives to this important discussion. Their goal is to provide a platform for exploring the real-world implications of ethical dilemmas, from the allocation of resources to the privacy concerns raised by emerging technologies. In their introductory episode, the hosts explain that the healthcare system is evolving rapidly, and with these changes come new ethical challenges that must be addressed.

The podcast will tackle a different topic each month, drawing on expert insights and real-life case studies. Listeners can expect to hear in-depth conversations on subjects ranging from the ethics of euthanasia to the intricacies of involuntary psychiatric care. Sisti and Levine emphasize that ethical considerations are not just academic, but affect everyday decisions in clinical practice, policy-making, and patient interactions.

By fostering these crucial dialogues, Sisti and Levine hope to help both medical professionals and the general public navigate the complexities of modern medicine. The podcast will be available on popular streaming platforms, and the hosts encourage listeners to subscribe and share the content with their networks.

Relevant disclosures for Sisti include Lykos Therapeutics and Tactogen. Relevant disclosures for include Levine include Compass Pathways.

Podcasts

"Medical Ethics Unpacked" is a new podcast hosted by Dominic Sisti, PhD, and Steve Levine, MD, focusing on ethical challenges in healthcare. The hosts aim to explore real-world implications of ethical dilemmas, such as resource allocation and privacy concerns, through monthly episodes featuring expert insights and case studies. Topics will include euthanasia and involuntary psychiatric care, emphasizing the practical impact of ethics on clinical practice and policy-making. The podcast seeks to guide medical professionals and the public in understanding modern medicine's complexities.

An introductory episode for Medical Ethics Unpacked, a monthly multimedia series hosted by medical ethicist Dominic Sisti, PhD, and psychiatrist Steven Levine, MD, exploring ethical issues in contemporary healthcare. 

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Medical Ethics Unpacked

Medical Ethics Unpacked is a regular multimedia series hosted by Dominic Sisti, PhD, and Steve Levine, MD, spotlighting a spectrum of topics within the field of medical ethics. Each month, Sisti, director of the Scattergood Program for Applied Ethics of Behavioral Healthcare in the Department of Medical Ethics and Health Policy at the University of Pennsylvania's Perelman School of Medicine, and Levine, a psychiatrist and senior vice president of Patient Access at Compass Pathways, will sit down for an in-depth discussion on a specific ethical dilemma within modern healthcare, with some episodes also featuring a special guest. 

Check back throughout the year for discussions on a variety of topics, including data privacy in health apps, euthanasia and medical assistance in dying, reproductive rights and technologies, and more!

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, Rare Disease Report, and Heart Trials.

Introducing Medical Ethics Unpacked, with Dominic Sisti, PhD, and Steve Levine, MD

Drs. Sperling and Gianos discuss future considerations for use of lipoprotein apheresis and the evolving landscape of lipid management.

HCPLive Special report Lipoprotein Apheresis Special Report Part 3

00:00 - Challenges and Barriers in Lipoprotein Apheresis

02:28 - Patient-facing and Clinician-Specific Perspectives

05:30 - Insurance and Health System Challenges 

12:07 - Final Thoughts and Recommendations

In contemporary settings within cardiology, the word 

 is enough to conjure excitement and enthusiasm. With the field on the cusp of a potential paradigm shift in the management of lipoprotein(a) [Lp(a)] within the next 18 months, many are optimistic about the potential for additional therapeutic options to improve outcomes in patients with elevated Lp(a).

What often goes unmentioned or overlooked in these conversations is the recognition of an existing US Food and Drug Administration-approved therapy for reducing Lp(a) in lipoprotein apheresis. Beyond this recognition, data and guidelines also support the role of lipoprotein apheresis in certain patients with familial hypercholesterolemia (FH).

The recognition of the potential utility of this therapy in this context and more was the subject of the latest 

scientific statement from the American Heart Association (AHA)

. Released on October 07, 2024, the statement, titled “Lipoprotein Apheresis: Utility, Outcomes, and Implementation in Clinical Practice: A Scientific Statement From the American Heart Association,”, clocks in at 18 pages and length and cites more than 100 references documents. Composed on behalf of several AHA councils, the document was created by a volunteer writing committee led by committee chair Laurence Sperling, MD, Katz Professor in Preventive Cardiology and founder of the Emory Center for Heart Disease Prevention, and vice-chair Eugenia Gianos, MD, director of Cardiovascular Prevention at Northwell Health.

In this, the third and final segment of this HCPLive Special Report, Sperling and Gianos discuss the evolution, challenges, and future of lipoprotein apheresis in treating patients with severe hypercholesterolemia. Sperling, who has overseen Emory’s lipoprotein apheresis program for more than 20 years, shares insights on the program’s expansion and the barriers faced in providing this treatment, which is currently available in only 33 US states. Sperling goes on to emphasizes the need for greater awareness among clinicians about the benefits of apheresis, which can drastically reduce LDL cholesterol and Lp(a) levels, improve patients' quality of life, and prevent cardiovascular events.

Gianos, who helped establish Northwell Health’s apheresis program, highlights the importance of balancing the inconvenience of frequent treatments with the long-term health benefits for patients. She also discusses the need for more research on patient experiences and the potential for the therapy to address not only lipid reduction but also inflammation and endothelial function. Both experts agree that while emerging therapies for Lp(a) are promising, apheresis remains a vital option for patients who do not respond optimally to existing treatments. Similarly, they both stress the importance of continued education and institutional support to ensure access to this life-saving therapy.

Clinical Application of Lipoprotein Apheresis

Laurence Sperling has no disclosures to report. Relevant disclosures for Gianos include Amgen, AstraZeneca, Eli Lilly and Company, kaenka, Novartis, and Med-IQ.

Gianos E, Duell PB, Toth PP, et al. Lipoprotein Apheresis: Utility, Outcomes, and Implementation in Clinical Practice: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. Published online October 7, 2024. doi:10.1161/ATV.0000000000000177

Iapoce C. AHA scientific statement promotes expanded use of lipoprotein apheresis. HCP Live. October 11, 2024. Accessed October 17, 2024. https://www.hcplive.com/view/aha-scientific-statement-promotes-expanded-use-of-lipoprotein-apheresis.

Videos

In part 3 of our Special Report on lipoprotein apheresis, Sperling and Gianos discuss future considerations for use and the evolving landscape of lipid management.

Dyslipidemia

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Video Series

The Future of Lipoprotein Apheresis, with Laurence Sperling, MD, and Eugenia Gianos, MD

In part 2 of this 3-part series, Sperling and Gianos highlight the role of lipoprotein apheresis in contemporary settings and the supporting evidence base. 

Optimizing Use and Clinical Considerations for Lipoprotein Apheresis, with Laurence Sperling, MD, and Eugenia Gianos, MD

Laurence Sperling, MD, and Eugenia Gianos, MD, discuss the historical context and underutilization of lipoprotein apheresis in part 1 of a 3-part video series.

Exploring the Role, History of Lipoprotein Apheresis, with Laurence Sperling, MD, and Eugenia Gianos, MD

Adherence to a preventative, favorable lifestyle significantly reduced CVD risk in participants with high and low genetic risk.

Gout

On the HCPLive gout page, resources on the topics of medical news and expert insight into gouty arthritis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on gout, and more.

High Genetic Gout Risk Associated With Increased Risk of CVD

Following the approval of sodium oxybate for cataplexy in adults with cataplexy, the FDA approves this indication for the pediatric population.

Sleep

On the HCPLive sleep page, resources on the topics of medical news and expert insight into sleep medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sleep apnea, insomnia, narcolepsy, and more.

FDA Approves Sodium Oxybate for Cataplexy, Excessive Daytime Sleepiness in Pediatric Narcolepsy

Abigail Brooks is an assistant editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The FDA has extended its review of the sNDA, delaying the previous October 15, 2024, PDUFA date, without providing a new anticipated action date.

Hepatology

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

FDA News

FDA Extends Review of Obeticholic Acid (Ocaliva) sNDA for Primary Biliary Cholangitis

This analysis was conducted to evaluate whether genetic risk of hidradenitis suppurativa was linked to greater risk of future cardiometabolic disease.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Patients with Genetic HS Susceptibility Predisposed to Coronary Artery Disease, Diabetes

A new study identifies antipsychotics to avoid for patients with schizophrenia who have cognitive deficits, including haloperidol, fluphenazine, and clozapine.

Schizophrenia

The HCPLive schizophrenia page is a resource for medical news and expert insights on the mental disorder. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for schizophrenia, and more.

Cognitive Deficits in Schizophrenia: Which Antipsychotics Should Be Avoided?

Adherence to an adapted low FODMAP diet and its impact on IBS symptoms were not affected based on the presence of fibromyalgia.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Irritable Bowel Syndrome

On the HCPLive irritable bowel syndrome page, resources on the topics of medical news and expert insight into IBS can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBS, IBD, and more.

Comorbid Fibromyalgia Does Not Impact Low FODMAP Diet Adherence, Outcomes for IBS

Findings from the study also continued to support a positive Ara h 2-sIgE as the single most important predictor of peanut allergy.

Food Allergy

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Appropriate Skin Prick Tests Can Limit Risk of Oral Food Challenges in Pediatric Allergies

 and joined the MJH Life Sciences team in April 2021. He graduated from The College of New Jersey with a degree in Journalism and Professional Writing. He enjoys listening to records, going to concerts, and playing with his cat Squish. You can reach him at 

Incorporating baked milk products into a regular diet may improve growth and quality of life in milk-allergic children.

Latest News

Study Identifies Gut Microbiome Makeup, Diversity Differences in People With Fibromyalgia

50% of Patients with Sepsis Admitted to the Emergency Department Die Within 2 years

Risankizumab (Skyrizi) Dose Optimization Effective, Safe for Patients with Psoriasis

Introducing Medical Ethics Unpacked, with Dominic Sisti, PhD, and Steve Levine, MD

The Future of Lipoprotein Apheresis, with Laurence Sperling, MD, and Eugenia Gianos, MD